Business Wire

FOURKITES

29.9.2021 11:14:07 CEST | Business Wire | Press release

Share
FourKites’ Industry-First Order Intelligence Hub Extends Real-Time Visibility to the Entire Order Lifecycle

FourKites® , the world’s leading real-time supply chain visibility platform , today introduced its Order Intelligence Hub, a new single-pane-of-glass view of the entire lifecycle of every order. By integrating order data, load information across modes, yard shipments, inventory visibility and other critical third-party systems, such as warehouse management systems and order management systems, shippers and their supply chain partners now have a powerful new tool to eliminate inefficiencies, manage exceptions, reduce expenses and increase customer satisfaction at every step of an order’s journey. With the goal of breaking down silos across systems, this solution was developed in close collaboration with major consumer packaged goods (CPG) customers and driven by insights from some of the largest companies in the Consumer Brand Association, which champions more than 1,700 leading CPG brands.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005410/en/

As part of the recently announced Supply Chain Health and Performance Task Force , the mission of which is to increase visibility and ease supply chain pressures across the CPG industry, FourKites worked closely with Consumer Brands and 15 of its members to identify common pain points and create a solution that would address those challenges by breaking down silos between teams and systems, and leveraging the scale of the FourKites network to provide unprecedented visibility into the CPG supply chain ecosystem . Through shared dashboards, participating members can take advantage of a real-time view of facilities, lanes and interchanges causing the most inefficiencies for CPG companies. With Order Intelligence Hub, users can drill down into the line-item level impacts of bottlenecks, and can then collaborate across teams to resolve those inefficiencies.

“Collaboration is essential for building modern, resilient supply chains,” said Tom Madrecki, vice president of supply chain and logistics at Consumer Brands. “The Supply Chain Health and Performance Task Force — in partnership with FourKites — is bringing more visibility, agility and data sharing to our supply chain, allowing the CPG industry to better navigate future challenges and ensure the reliable delivery of essential goods.”

By eliminating silos and integrating disparate systems, FourKites’ Order Intelligence Hub enables collaboration and insight throughout the lifecycle of every order. Teams can much more effectively manage exceptions by identifying issues and their root causes in real time, anywhere. Customisable, persona-based dashboards provide every stakeholder group — from supply planning through to customer service and facilities management — with the data and metrics that matter most to them. And the entire community benefits from FourKites‘ market-leading network data set, collected via working with more of the world’s leading brands than any other visibility provider, including 18 of the top-20 F&B brands and nine of the top-10 CPG companies.

“The Order Intelligence Hub is a big milestone as we execute on our vision to connect the physical and digital worlds of warehouses, stores and transportation with real-time data and machine learning,” said Mathew Elenjickal, founder and CEO of FourKites. “Collaborating with our customers and other industry leaders, like Consumer Brands, in product development has enabled us to bring to market some of the most innovative solutions that address the industry’s most critical pain points.”

With the Order Intelligence Hub, FourKites builds on its long history of industry-first innovations , including multimodal purchase order tracking , which provides line-item level shipment detail using PO numbers, and Dynamic Yard , which gives enterprises the ability to proactively manage all of their facilities based on real-time, in-yard freight data and analytics. FourKites and its largest customers, which ship some of the world’s leading brands to locations around the world, have integrated previously siloed systems across customer service, transportation planning, supply/demand planning and warehouse management to enable internal stakeholder communication and insights throughout the lifecycle of every order.

About FourKites

FourKites® is a leading global supply chain visibility platform, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching 176 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 620 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/ .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye